173 related articles for article (PubMed ID: 37642751)
1. Effect of chemotherapy and different chemotherapy regimens on bone health among Chinese breast cancer women in different menstrual status: a self-control study.
Peng BQ; Wu J; Tian S; Qu XQ; Liang XY; Feng JH; Chen YL; She RL; Ma CY; Song JY; Li ZX; Jiang ZY; Wu KN; Kong LQ
Support Care Cancer; 2023 Aug; 31(9):540. PubMed ID: 37642751
[TBL] [Abstract][Full Text] [Related]
2. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
Zhang Y; Wang Y
J Nutr Health Aging; 2020; 24(5):485-493. PubMed ID: 32346686
[TBL] [Abstract][Full Text] [Related]
3. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
[TBL] [Abstract][Full Text] [Related]
5. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
Cameron DA; Douglas S; Brown JE; Anderson RA
Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
Monroy-Cisneros K; Esparza-Romero J; Valencia ME; Guevara-Torres AG; Méndez-Estrada RO; Anduro-Corona I; Astiazarán-García H
BMC Cancer; 2016 Nov; 16(1):860. PubMed ID: 27821086
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial of Exercise to Prevent Bone Loss in Premenopausal Women with Breast Cancer.
Tabatabai LS; Bloom J; Stewart S; Sellmeyer DE
J Womens Health (Larchmt); 2019 Jan; 28(1):87-92. PubMed ID: 30312118
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
11. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
[TBL] [Abstract][Full Text] [Related]
12. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
[TBL] [Abstract][Full Text] [Related]
14. Bone health in urban midlife Malaysian women: risk factors and prevention.
Lim PS; Ong FB; Adeeb N; Seri SS; Noor-Aini MY; Shamsuddin K; Hapizah N; Mohamed AL; Mokhtar A; Wan HW
Osteoporos Int; 2005 Dec; 16(12):2069-79. PubMed ID: 16234999
[TBL] [Abstract][Full Text] [Related]
15. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer.
Christensen CØ; Cronin-Fenton D; Frøslev T; Hermann AP; Ewertz M
Support Care Cancer; 2016 Oct; 24(10):4229-36. PubMed ID: 27146497
[TBL] [Abstract][Full Text] [Related]
16. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
[TBL] [Abstract][Full Text] [Related]
17. Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study.
Qu XL; Zheng B; Chen TY; Cao ZR; Qu B; Jiang T
Orthop Surg; 2020 Feb; 12(1):116-123. PubMed ID: 31880071
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
[TBL] [Abstract][Full Text] [Related]
19. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
20. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
